136 related articles for article (PubMed ID: 24222478)
1. Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide.
Neuner P; Peier AM; Talamo F; Ingallinella P; Lahm A; Barbato G; Di Marco A; Desai K; Zytko K; Qian Y; Du X; Ricci D; Monteagudo E; Laufer R; Pocai A; Bianchi E; Marsh DJ; Pessi A
J Pept Sci; 2014 Jan; 20(1):7-19. PubMed ID: 24222478
[TBL] [Abstract][Full Text] [Related]
2. PEGylation of Neuromedin U yields a promising candidate for the treatment of obesity and diabetes.
Ingallinella P; Peier AM; Pocai A; Marco AD; Desai K; Zytko K; Qian Y; Du X; Cellucci A; Monteagudo E; Laufer R; Bianchi E; Marsh DJ; Pessi A
Bioorg Med Chem; 2012 Aug; 20(15):4751-9. PubMed ID: 22771182
[TBL] [Abstract][Full Text] [Related]
3. A PEGylated analog of short-length Neuromedin U with potent anorectic and anti-obesity effects.
Inooka H; Sakamoto K; Shinohara T; Masuda Y; Terada M; Kumano S; Yokoyama K; Noguchi J; Nishizawa N; Kamiguchi H; Fujita H; Asami T; Takekawa S; Ohtaki T
Bioorg Med Chem; 2017 Apr; 25(8):2307-2312. PubMed ID: 28291683
[TBL] [Abstract][Full Text] [Related]
4. Potent Body Weight-Lowering Effect of a Neuromedin U Receptor 2-selective PEGylated Peptide.
Kanematsu-Yamaki Y; Nishizawa N; Kaisho T; Nagai H; Mochida T; Asakawa T; Inooka H; Dote K; Fujita H; Matsumiya K; Hirabayashi H; Sakamoto J; Ohtaki T; Takekawa S; Asami T
J Med Chem; 2017 Jul; 60(14):6089-6097. PubMed ID: 28657315
[TBL] [Abstract][Full Text] [Related]
5. PEGylated neuromedin U-8 shows long-lasting anorectic activity and anti-obesity effect in mice by peripheral administration.
Masuda Y; Kumano S; Noguchi J; Sakamoto K; Inooka H; Ohtaki T
Peptides; 2017 Aug; 94():99-105. PubMed ID: 28400225
[TBL] [Abstract][Full Text] [Related]
6. Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.
Kaisho T; Nagai H; Asakawa T; Suzuki N; Fujita H; Matsumiya K; Nishizawa N; Kanematsu-Yamaki Y; Dote K; Sakamoto JI; Asami T; Takekawa S
Int J Obes (Lond); 2017 Dec; 41(12):1790-1797. PubMed ID: 28757640
[TBL] [Abstract][Full Text] [Related]
7. Effects of peripherally administered neuromedin U on energy and glucose homeostasis.
Peier AM; Desai K; Hubert J; Du X; Yang L; Qian Y; Kosinski JR; Metzger JM; Pocai A; Nawrocki AR; Langdon RB; Marsh DJ
Endocrinology; 2011 Jul; 152(7):2644-54. PubMed ID: 21586559
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.
Kim I; Kim TH; Ma K; Lee ES; Kim D; Oh KT; Lee DH; Lee KC; Youn YS
Bioconjug Chem; 2010 Aug; 21(8):1513-9. PubMed ID: 20715855
[TBL] [Abstract][Full Text] [Related]
9. Development of potent and proteolytically stable human neuromedin U receptor agonists.
De Prins A; Martin C; Van Wanseele Y; Skov LJ; Tömböly C; Tourwé D; Caveliers V; Van Eeckhaut A; Holst B; Rosenkilde MM; Smolders I; Ballet S
Eur J Med Chem; 2018 Jan; 144():887-897. PubMed ID: 29329072
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake.
Dalbøge LS; Pedersen SL; van Witteloostuijn SB; Rasmussen JE; Rigbolt KT; Jensen KJ; Holst B; Vrang N; Jelsing J
J Pept Sci; 2015 Feb; 21(2):85-94. PubMed ID: 25521062
[TBL] [Abstract][Full Text] [Related]
11. Discovery and pharmacological characterization of a small-molecule antagonist at neuromedin U receptor NMUR2.
Liu JJ; Payza K; Huang J; Liu R; Chen T; Coupal M; Laird JM; Cao CQ; Butterworth J; Lapointe S; Bayrakdarian M; Trivedi S; Bostwick JR
J Pharmacol Exp Ther; 2009 Jul; 330(1):268-75. PubMed ID: 19369576
[TBL] [Abstract][Full Text] [Related]
12. Small lipidated anti-obesity compounds derived from neuromedin U.
Micewicz ED; Bahattab OS; Willars GB; Waring AJ; Navab M; Whitelegge JP; McBride WH; Ruchala P
Eur J Med Chem; 2015 Aug; 101():616-26. PubMed ID: 26204509
[TBL] [Abstract][Full Text] [Related]
13. A potent neuromedin U receptor 2-selective alkylated peptide.
Nishizawa N; Kanematsu-Yamaki Y; Funata M; Nagai H; Shimizu A; Fujita H; Sakamoto J; Takekawa S; Asami T
Bioorg Med Chem Lett; 2017 Oct; 27(20):4626-4629. PubMed ID: 28935264
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of albumin conjugates of a truncated peptide YY analogue for half-life extension.
Ehrlich GK; Michel H; Truitt T; Riboulet W; Pop-Damkov P; Goelzer P; Hainzl D; Qureshi F; Lueckel B; Danho W; Conde-Knape K; Konkar A
Bioconjug Chem; 2013 Dec; 24(12):2015-24. PubMed ID: 24251972
[TBL] [Abstract][Full Text] [Related]
15. Neuromedin U inhibits food intake partly by inhibiting gastric emptying.
Dalbøge LS; Pedersen SL; Secher T; Holst B; Vrang N; Jelsing J
Peptides; 2015 Jul; 69():56-65. PubMed ID: 25895852
[TBL] [Abstract][Full Text] [Related]
16. Central effects of neuromedin U in the regulation of energy homeostasis.
Nakazato M; Hanada R; Murakami N; Date Y; Mondal MS; Kojima M; Yoshimatsu H; Kangawa K; Matsukura S
Biochem Biophys Res Commun; 2000 Oct; 277(1):191-4. PubMed ID: 11027662
[TBL] [Abstract][Full Text] [Related]
17. Central NMU signaling in body weight and energy balance regulation: evidence from NMUR2 deletion and chronic central NMU treatment in mice.
Egecioglu E; Ploj K; Xu X; Bjursell M; Salomé N; Andersson N; Ohlsson C; Taube M; Hansson C; Bohlooly-Y M; Morgan DG; Dickson SL
Am J Physiol Endocrinol Metab; 2009 Sep; 297(3):E708-16. PubMed ID: 19584200
[TBL] [Abstract][Full Text] [Related]
18. The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).
Peier A; Kosinski J; Cox-York K; Qian Y; Desai K; Feng Y; Trivedi P; Hastings N; Marsh DJ
Endocrinology; 2009 Jul; 150(7):3101-9. PubMed ID: 19324999
[TBL] [Abstract][Full Text] [Related]
19. Neuromedin U can exert colon-specific, enteric nerve-mediated prokinetic activity, via a pathway involving NMU1 receptor activation.
Dass NB; Bassil AK; North-Laidler VJ; Morrow R; Aziz E; Tuladhar BR; Sanger GJ
Br J Pharmacol; 2007 Feb; 150(4):502-8. PubMed ID: 17211455
[TBL] [Abstract][Full Text] [Related]
20. Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris.
Huang YS; Chen Z; Chen YQ; Ma GC; Shan JF; Liu W; Zhou LF
J Pept Sci; 2008 May; 14(5):588-95. PubMed ID: 17994612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
